

## ■ CML PocketCard 2013

Based on the recent publication of the 2013 European LeukemiaNet recommendations for the management of chronic myeloid leukemia the CML pocket card was updated. The new pocket card in PDF format and the related order form are now available online. ▶ [CML PocketCard 2013](#)

## ■ ELN mid-term report for the European Science Foundation (ESF)

From July 2010 to June 2015, the European LeukemiaNet is funded through a research networking programme initiated by the ESF. The mid-term report summarizing ELN's activities of the past three years was recently submitted to the ESF. The report can now be downloaded from the website. ▶ [mid-term report](#)

## ■ ELN guidelines and recommendations

The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have laid the groundwork for uniform definitions and standards required for common clinical trials and projects. An update of the collection of the ELN guidelines and recommendations developed since 2006 is now available. ▶ [collection of ELN guidelines and recommendations](#)

## ■ Update of WP participants

On a half-yearly basis the contact data of active WP participants are updated on the website. The most recent lists as well as short overviews of the respective lead participants are online now. Please find these lists including the participant's organization, nationality and e-mail address in the section "contact" of every workpackage. ▶ [contact NMC for changes](#)

## ■ Publications from the Network (selected)

### Acute lymphoblastic leukemia

- ▶ Burmeister T et al. Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma. *Mol Oncol*. 2013 Aug;7(4):850-8.
- ▶ Gökbuget N. How I treat older patients with ALL. *Blood*. 2013 Aug 22;122(8):1366-75.
- ▶ Grammatico S et al. Lineage switch from pro-B acute lymphoid leukemia to acute myeloid leukemia in a case with t(12;17)(p13;q11)/TAF15-ZNF384 rearrangement. *Leuk Lymphoma*. 2013 Aug;54(8):1802-5.
- ▶ Hoelzer D. CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia. *Cancer*. 2013 Aug 1;119(15):2671-4.

### Acute myeloid leukemia

- ▶ Christopheit M et al. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. *Bone Marrow Transplant*. 2013 Sep;48(9):1257-9.
- ▶ Clarhaut J et al. A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts. *Leuk Res*. 2013 Aug;37(8):948-55.
- ▶ Greiner J et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). *Blood*. 2013 Aug 8;122(6):1087-8.
- ▶ Grossmann V et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based

on cytogenetic and molecular genetic characteristics. *Leukemia*. 2013 Sep;27(9):1940-3.

- ▶ Grossmann V et al. High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia. *Leukemia*. 2013 Sep;27(9):1933-6.
- ▶ Hoyos M et al. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. *Eur J Haematol*. 2013 Sep;91(3):209-18.
- ▶ Iacobucci I et al. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. *Pharmacogenomics J*. 2013 Aug;13(4):335-41.
- ▶ Opatz S et al. Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. *Blood*. 2013 Sep 5;122(10):1761-9.
- ▶ Ruben JM et al. Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. *Immunotherapy*. 2013 Aug;5(8):859-68.
- ▶ Sarkozy C et al. Outcome of older patients with acute myeloid leukemia in first relapse. *Am J Hematol*. 2013 Sep;88(9):758-64.
- ▶ Schlenk RF et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*. 2013 Aug 29;122(9):1576-82.
- ▶ Taylor G et al. Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals. *Int J Hematol*. 2013 Sep;98(3):267-8.
- ▶ Yomade O et al. Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. *Ann Hematol*. 2013 Aug;92(8):1071-7.

### **Chronic myeloid leukemia**

- ▶ Baccarani M et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*. 2013 Aug 8;122(6):872-84.
- ▶ Höglund M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. *Blood*. 2013 Aug 15;122(7):1284-92.
- ▶ Marcé S et al. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. *Med Clin (Barc)*. 2013 Aug 4;141(3):95-9.
- ▶ Onida F et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. *Haematologica*. 2013 Sep;98(9):1344-52.
- ▶ Pastore F et al. Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. *Exp Hematol Oncol*. 2013 Sep 5;2(1):24.
- ▶ Terpos E et al. Imatinib and chronic myeloid leukemia: close to the bone. *Leuk Lymphoma*. 2013 Aug;54(8):1581-2.
- ▶ Thielen N et al. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. *Ann Hematol*. 2013 Aug;92(8):1049-56.
- ▶ Uz B et al. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. *Hematology*. 2013 Sep;18(5):247-52.

### **Chronic lymphocytic leukemia**

- ▶ Cramer P et al. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. *Leuk Lymphoma*. 2013 Aug;54(8):1821-2.
- ▶ Ferrer G et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. *Leuk Lymphoma*. 2013 Sep;54(9):2016-22.

- ▶ Fink AM et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. *Leukemia*. 2013 Sep;27(9):1949-52.
- ▶ Göbel M et al. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. *PLoS One*. 2013 Aug 23;8(8):e72107.
- ▶ Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. *Am J Hematol*. 2013 Sep;88(9):803-16.
- ▶ Herold T et al. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. *Leuk Lymphoma*. 2013 Aug;54(8):1652-7.
- ▶ Schnaiter A et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. *Blood*. 2013 Aug 15;122(7):1266-70.

### **Myelodysplastic syndromes**

- ▶ Bräulke F et al. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. *Leuk Res*. 2013 Aug;37(8):900-6.

### **Myeloproliferative neoplasms**

- ▶ Barbui T et al. Myeloproliferative neoplasms and thrombosis. *Blood*. 2013 Sep 26;122(13):2176-84.
- ▶ Iannotto JC et al. Efficacy and safety of pegylated-interferon  $\alpha$ -2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. *Br J Haematol*. 2013 Sep;162(6):783-91.
- ▶ Oaks JJ et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. *Blood*. 2013 Sep 12;122(11):1923-34.
- ▶ Susini MC et al. The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. *Br J Haematol*. 2013 Aug;162(3):424-7.
- ▶ Tefferi A et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*. 2013 Aug 22;122(8):1395-8.
- ▶ Tefferi A et al. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. *Leukemia*. 2013 Aug;27(8):1617-20.
- ▶ Tefferi A et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia*. 2013 Sep;27(9):1874-81.
- ▶ Vannucchi AM et al. Mutations and prognosis in primary myelofibrosis. *Leukemia*. 2013 Sep;27(9):1861-9.

### **Myelodysplastic/Myeloproliferative neoplasms**

- ▶ Broséus J et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. *Leukemia*. 2013 Sep;27(9):1826-31.
- ▶ Meggendorfer M et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. *Leukemia*. 2013 Sep;27(9):1852-60.

### **Diagnostics**

- ▶ Béné MC et al. ICSH/ICCS practice guidelines special issue. *Cytometry B Clin Cytom*. 2013 Sep;84(5):279-80.
- ▶ Dolz S et al. Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia. *J Mol Diagn*. 2013 Sep;15(5):678-86.
- ▶ Rinke J et al. Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA. *Clin Chem*. 2013 Aug;59(8):1238-50.
- ▶ Soverini S et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. *Blood*. 2013 Aug 29;122(9):1634-48.

- ▶ Wood B et al. Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria. *Cytometry B Clin Cytom.* 2013 Sep;84(5):315-23.

### Stem cell transplantation

- ▶ Christopheit M et al. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. *J Clin Oncol.* 2013 Sep 10;31(26):3259-3271.
- ▶ Girerd S et al. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience. *Bone Marrow Transplant.* 2013 Sep;48(9):1243-8.
- ▶ Gratwohl A et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. *Haematologica.* 2013 Aug;98(8):1282-90.
- ▶ Ringdén O et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. *J Intern Med.* 2013 Aug;274(2):153-62. Sanz J et al. Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. *Biol Blood Marrow Transplant.* 2013 Sep;19(9):1387-92.
- ▶ Spies-Weissart B et al. Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). *J Cancer Res Clin Oncol.* 2013 Aug;139(8):1397-404.
- ▶ Styczynski J et al. Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working party of the European group for blood and marrow transplantation. *Clin Infect Dis.* 2013 Sep;57(6):794-802.

### Infectious diseases

- ▶ Ljungman P. CMV: a warrior against leukemia? *Blood.* 2013 Aug 15;122(7):1101-2.

## ■ New trials in the ELTR

- ASPIRE** A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
- CHOICES** A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR)
- B1931022** An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
- PEGASYS** Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)